IL308759A - Checkpoint kinase 1 (CHK1) inhibitors and uses thereof - Google Patents
Checkpoint kinase 1 (CHK1) inhibitors and uses thereofInfo
- Publication number
- IL308759A IL308759A IL308759A IL30875923A IL308759A IL 308759 A IL308759 A IL 308759A IL 308759 A IL308759 A IL 308759A IL 30875923 A IL30875923 A IL 30875923A IL 308759 A IL308759 A IL 308759A
- Authority
- IL
- Israel
- Prior art keywords
- chk1
- inhibitors
- checkpoint kinase
- checkpoint
- kinase
- Prior art date
Links
- 101150050673 CHK1 gene Proteins 0.000 title 1
- 102000006459 Checkpoint Kinase 1 Human genes 0.000 title 1
- 108010019244 Checkpoint Kinase 1 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163193990P | 2021-05-27 | 2021-05-27 | |
| PCT/US2022/031141 WO2022251502A1 (en) | 2021-05-27 | 2022-05-26 | Checkpoint kinase 1 (chk1) inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL308759A true IL308759A (en) | 2024-01-01 |
Family
ID=84229213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL308759A IL308759A (en) | 2021-05-27 | 2022-05-26 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11707462B2 (enExample) |
| EP (1) | EP4347582A4 (enExample) |
| JP (1) | JP2024520481A (enExample) |
| KR (1) | KR20240021188A (enExample) |
| CN (1) | CN117715905A (enExample) |
| AU (1) | AU2022282384A1 (enExample) |
| BR (1) | BR112023024571A2 (enExample) |
| CA (1) | CA3219348A1 (enExample) |
| IL (1) | IL308759A (enExample) |
| MX (1) | MX2023014028A (enExample) |
| TW (1) | TW202313588A (enExample) |
| WO (1) | WO2022251502A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023002453A2 (pt) | 2020-08-12 | 2023-05-02 | Boundless Bio Inc | Composições de agente de via de estresse de replicação e métodos para tratar câncer |
| MX2023006364A (es) * | 2020-11-30 | 2023-06-13 | Sumitomo Pharma Co Ltd | Derivado de 5-heteroaril-1h-pirazol-3-amina. |
| EP4347582A4 (en) | 2021-05-27 | 2025-05-07 | Boundless Bio, Inc. | CHECKPOINT KINASE-1 INHIBITORS AND USES THEREOF |
| CA3241992A1 (en) * | 2021-12-24 | 2023-06-29 | Seiji Kamioka | 1h-pyrazole-3-amine derivative having bicyclic backbone |
| CN119546588A (zh) * | 2022-05-24 | 2025-02-28 | 无界生物公司 | 吡啶检查点激酶1（chk1）抑制剂及其用途 |
| CN119255990A (zh) * | 2022-05-25 | 2025-01-03 | 曙方医药 | 作为检查点激酶1抑制剂的含氮五元杂环衍生物及其用途 |
| EP4626433A1 (en) * | 2022-11-29 | 2025-10-08 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof |
| TW202440549A (zh) * | 2022-11-29 | 2024-10-16 | 美商無界生物公司 | 檢查點激酶１（ｃｈｋ１）抑制劑及其用途 |
| EP4683635A1 (en) * | 2023-03-20 | 2026-01-28 | Boundless Bio, Inc. | Uses of a checkpoint kinase 1 (chk1) inhibitor |
| JP2026513823A (ja) * | 2023-04-03 | 2026-05-01 | バウンドレス バイオ，インク． | チェックポイントキナーゼ１（ｃｈｋ１）阻害剤の結晶形態およびその使用 |
| US20260232659A1 (en) * | 2023-04-03 | 2026-08-13 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitor pharmaceutical composition |
| EP4753712A1 (en) * | 2023-08-02 | 2026-06-10 | Health Research, Inc. | Sequential treatment method for p53-deficient cancer |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026108769A1 (en) | 2024-11-19 | 2026-05-28 | Groovy Medicine (Hangzhou) Ltd. | Substituted 2- [ (5-cyanopyrazin-2-yl) amino] pyridines, their prodrugs and uses thereof |
| WO2026108771A2 (en) | 2024-11-19 | 2026-05-28 | Groovy Medicine (Hangzhou) Ltd. | Substituted heteroaromatic compounds as inhibitors of checkpoint kinase 1 and notch signaling pathway and uses thereof |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
| CN122031724A (zh) * | 2026-04-17 | 2026-05-15 | 中国科学院杭州医学研究所 | 编码p16蛋白的mRNA在制备用于治疗胰腺癌的药物中的应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0110302A (pt) * | 2000-04-18 | 2003-01-14 | Agouron Pharma | Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase |
| US20050209297A1 (en) * | 2000-08-31 | 2005-09-22 | Pfizer Inc | Pyrazole derivatives |
| DZ3398A1 (fr) * | 2000-08-31 | 2002-03-07 | Pfizer Prod Inc | Derives pyrazole et leur utilisation comme inhibiteurs des proteines kinases |
| PA8850801A1 (es) * | 2008-12-17 | 2010-07-27 | Lilly Co Eli | Compuestos útiles para inhibir chk1 |
| GB201402277D0 (en) * | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| CA3013514C (en) * | 2016-02-04 | 2021-11-23 | Pharmaengine, Inc. | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications |
| KR20220042159A (ko) * | 2019-08-01 | 2022-04-04 | 인테그랄 바이오사이언스 피브이티. 엘티디. | 키나제 억제제로서의 헤테로사이클릭 화합물 및 이의 용도 |
| CN112457306A (zh) * | 2019-09-06 | 2021-03-09 | 上海瑛派药业有限公司 | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 |
| CN111253370B (zh) | 2020-03-24 | 2021-08-03 | 浙江大学 | N-多取代吡啶-2-氨基嘧啶类衍生物及用途 |
| EP4741018A3 (en) * | 2020-06-19 | 2026-07-15 | Anaxis Pharma Pty Ltd | Sulphonamide compounds |
| BR112023002453A2 (pt) | 2020-08-12 | 2023-05-02 | Boundless Bio Inc | Composições de agente de via de estresse de replicação e métodos para tratar câncer |
| WO2022087326A1 (en) | 2020-10-23 | 2022-04-28 | Celgene Corporation | Heterocyclic compounds and their use for treatment of helminthic infections and diseases |
| US11564920B2 (en) | 2020-11-30 | 2023-01-31 | Sumitomo Pharma Co., Ltd. | 5-heteroaryl-1H-pyrazol-3-amine derivative |
| MX2023006364A (es) * | 2020-11-30 | 2023-06-13 | Sumitomo Pharma Co Ltd | Derivado de 5-heteroaril-1h-pirazol-3-amina. |
| EP4347582A4 (en) | 2021-05-27 | 2025-05-07 | Boundless Bio, Inc. | CHECKPOINT KINASE-1 INHIBITORS AND USES THEREOF |
| CA3241992A1 (en) | 2021-12-24 | 2023-06-29 | Seiji Kamioka | 1h-pyrazole-3-amine derivative having bicyclic backbone |
| CN119546588A (zh) | 2022-05-24 | 2025-02-28 | 无界生物公司 | 吡啶检查点激酶1（chk1）抑制剂及其用途 |
| CN119255990A (zh) | 2022-05-25 | 2025-01-03 | 曙方医药 | 作为检查点激酶1抑制剂的含氮五元杂环衍生物及其用途 |
| JPWO2023229032A1 (enExample) | 2022-05-27 | 2023-11-30 | ||
| TW202440549A (zh) | 2022-11-29 | 2024-10-16 | 美商無界生物公司 | 檢查點激酶１（ｃｈｋ１）抑制劑及其用途 |
| EP4626433A1 (en) | 2022-11-29 | 2025-10-08 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof |
| EP4683635A1 (en) | 2023-03-20 | 2026-01-28 | Boundless Bio, Inc. | Uses of a checkpoint kinase 1 (chk1) inhibitor |
| JP2026513823A (ja) | 2023-04-03 | 2026-05-01 | バウンドレス バイオ，インク． | チェックポイントキナーゼ１（ｃｈｋ１）阻害剤の結晶形態およびその使用 |
| US20260232659A1 (en) | 2023-04-03 | 2026-08-13 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitor pharmaceutical composition |
-
2022
- 2022-05-26 EP EP22812165.3A patent/EP4347582A4/en active Pending
- 2022-05-26 MX MX2023014028A patent/MX2023014028A/es unknown
- 2022-05-26 BR BR112023024571A patent/BR112023024571A2/pt unknown
- 2022-05-26 WO PCT/US2022/031141 patent/WO2022251502A1/en not_active Ceased
- 2022-05-26 TW TW111119737A patent/TW202313588A/zh unknown
- 2022-05-26 IL IL308759A patent/IL308759A/en unknown
- 2022-05-26 CA CA3219348A patent/CA3219348A1/en active Pending
- 2022-05-26 KR KR1020237044236A patent/KR20240021188A/ko active Pending
- 2022-05-26 CN CN202280052765.2A patent/CN117715905A/zh active Pending
- 2022-05-26 AU AU2022282384A patent/AU2022282384A1/en not_active Abandoned
- 2022-05-26 JP JP2023573047A patent/JP2024520481A/ja active Pending
- 2022-08-29 US US17/897,667 patent/US11707462B2/en active Active
-
2023
- 2023-06-01 US US18/327,775 patent/US12527790B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4347582A1 (en) | 2024-04-10 |
| BR112023024571A2 (pt) | 2024-02-06 |
| AU2022282384A1 (en) | 2023-12-14 |
| MX2023014028A (es) | 2023-12-12 |
| KR20240021188A (ko) | 2024-02-16 |
| US12527790B2 (en) | 2026-01-20 |
| TW202313588A (zh) | 2023-04-01 |
| EP4347582A4 (en) | 2025-05-07 |
| CN117715905A (zh) | 2024-03-15 |
| JP2024520481A (ja) | 2024-05-24 |
| US20230026313A1 (en) | 2023-01-26 |
| CA3219348A1 (en) | 2022-12-01 |
| US11707462B2 (en) | 2023-07-25 |
| WO2022251502A1 (en) | 2022-12-01 |
| US20230310423A1 (en) | 2023-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL317138A (en) | Pyridine checkpoint kinase 1 (CHK1) inhibitors and their uses | |
| EP4347582A4 (en) | CHECKPOINT KINASE-1 INHIBITORS AND USES THEREOF | |
| SG11202104344RA (en) | An aurora a kinase inhibitor for use in the treatment of neuroblastoma | |
| IL307187A (en) | MK2 inhibitors and their uses | |
| IL300107A (en) | HSD17B13 quinazolinone inhibitors and uses thereof | |
| SG11202108702XA (en) | Cyclin-dependent kinase 2 biomarkers and uses thereof | |
| SG11202103142TA (en) | Heterocyclic kinase inhibitors and uses thereof | |
| EP3868762A4 (en) | Mst1 kinase inhibitor and use thereof | |
| HUE057976T2 (hu) | Chekpoint-kináz 1 (CHK1) inhibitorként alkalmazható 3,5-diszubsztituált pirazolok, elõállításuk és alkalmazásuk | |
| ES3065238T3 (en) | Heterocyclic pad4 inhibitors | |
| NZ730771A (en) | Aurora a kinase inhibitor | |
| ZA200408386B (en) | Substituted benzazoles and use thereof as Raf kinase inhibitors | |
| ZA200801441B (en) | p38MAP kinase inhibitors and methods for using the same | |
| IL188932A0 (en) | Sphingosine kinase inhibitors and methods of their use | |
| MX343669B (es) | Combinacion de inhibidores de la cinasa de control 1 inhibidores de la cinasa wee 1. | |
| SG10201913927VA (en) | Kinase inhibitors and uses thereof | |
| EP4469449A4 (en) | PARP1 INHIBITORS AND THEIR USES | |
| IL275463A (en) | TLR7/8 antagonists and their use | |
| ZA202109737B (en) | Compound used as kinase inhibitor and application thereof | |
| EP4479403A4 (en) | MEMBRANE-ASSOCIATED TYROSINE AND THREONIN-SPECIFIC CDC2 KINASE INHIBITORS (PKMYT1) AND THEIR USES | |
| PL4337673T3 (pl) | Inhibitory psd-95 i ich zastosowania | |
| EP4219456A4 (en) | CSF1R KINASE INHIBITORS AND USE THEREOF | |
| IL307873A (en) | Heterocyclic compounds and their uses | |
| EP4132921A4 (en) | Pi3 kinase inhibitors and uses thereof | |
| IL312466A (en) | PI3K-alpha inhibitors and methods for their preparation and use |